生命科学资讯

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

CDC moves to cut $600M in grants to Democrat-led states

Madrigal turns to RNAi drugs from China to bolster MASH pipeline

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

FDA refuses to review Moderna’s mRNA flu vaccine

Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug

Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study

FDA rejects Regenxbio treatment in another blow to gene therapy

Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals

Lilly bets again on China drugs; Roche showcases MS data

Takeda, Iambic partner in latest pharma AI push

Hengrui, Kailera tout positive results for dual-acting obesity pill

Small and mighty: single-domain antibodies pack a biological punch

Navigating the complexities of Cell and Gene Therapy supply chains

Hims cancels plans to sell compounded GLP-1 pill after FDA backlash

White House’s online service for drug sales debuts with limited impact on prices

Agomab, SpyGlass bank a combined $350M in biotech IPOs

Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game

Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

Bayer details anticipated stroke prevention data for new blood-thinner